2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses biomarker research in breast cancer.
Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses biomarker research in breast cancer.
Molecular assays are used to make decisions of whether to give chemotherapy to patients or for prognostic reasons. According to O’Regan, it would interesting to use one of the existing assays, such as 21-Gene Recurrence Score, to determine which patients need a more intensive treatment.
Currently, no RNA has been extracted but that is something that could make sense as a biomarker for these patients.
Related Content: